drugset / Trial / NCT00790010
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Phase 1
Completed
46 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collabGenentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely. This study also seeks to investigate whether using both study drugs lengthens the amount of time before the participants melanoma worsens.
Timeline
- Start
- 2009-02-26
- Primary completion
- 2018-06-22
- Completion
- 2018-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |